Browse PRDX1

Summary
SymbolPRDX1
Nameperoxiredoxin 1
Aliases NKEFA; PAGA; MSP23; NKEF-A; PRXI; natural killer cell-enhancing factor A; natural killer-enhancing factor A; ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Melanosome Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV.
Domain PF10417 C-terminal domain of 1-Cys peroxiredoxin
PF00578 AhpC/TSA family
Function

Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2) (PubMed:9497357). Reduces an intramolecular disulfide bond in GDPD5 that gates the ability to GDPD5 to drive postmitotic motor neuron differentiation (By similarity).

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0000303 response to superoxide
GO:0000305 response to oxygen radical
GO:0001501 skeletal system development
GO:0001894 tissue homeostasis
GO:0001895 retina homeostasis
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0002228 natural killer cell mediated immunity
GO:0002262 myeloid cell homeostasis
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0006606 protein import into nucleus
GO:0006801 superoxide metabolic process
GO:0006913 nucleocytoplasmic transport
GO:0006979 response to oxidative stress
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0009636 response to toxic substance
GO:0010035 response to inorganic substance
GO:0017038 protein import
GO:0019430 removal of superoxide radicals
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031503 protein complex localization
GO:0032386 regulation of intracellular transport
GO:0032872 regulation of stress-activated MAPK cascade
GO:0033157 regulation of intracellular protein transport
GO:0034101 erythrocyte homeostasis
GO:0034504 protein localization to nucleus
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0042267 natural killer cell mediated cytotoxicity
GO:0042306 regulation of protein import into nucleus
GO:0042345 regulation of NF-kappaB import into nucleus
GO:0042348 NF-kappaB import into nucleus
GO:0042743 hydrogen peroxide metabolic process
GO:0042744 hydrogen peroxide catabolic process
GO:0042990 regulation of transcription factor import into nucleus
GO:0042991 transcription factor import into nucleus
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0044744 protein targeting to nucleus
GO:0045454 cell redox homeostasis
GO:0046822 regulation of nucleocytoplasmic transport
GO:0048871 multicellular organismal homeostasis
GO:0048872 homeostasis of number of cells
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051403 stress-activated MAPK cascade
GO:0060249 anatomical structure homeostasis
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0071450 cellular response to oxygen radical
GO:0071451 cellular response to superoxide
GO:0072593 reactive oxygen species metabolic process
GO:0098754 detoxification
GO:0098869 cellular oxidant detoxification
GO:1900180 regulation of protein localization to nucleus
GO:1902593 single-organism nuclear import
GO:1903533 regulation of protein targeting
GO:1904589 regulation of protein import
GO:1990748 cellular detoxification
Molecular Function GO:0004601 peroxidase activity
GO:0008379 thioredoxin peroxidase activity
GO:0016209 antioxidant activity
GO:0016684 oxidoreductase activity, acting on peroxide as acceptor
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0051920 peroxiredoxin activity
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005913 cell-cell adherens junction
GO:0042470 melanosome
GO:0043209 myelin sheath
GO:0048770 pigment granule
> KEGG and Reactome Pathway
 
KEGG hsa04146 Peroxisome
Reactome R-HSA-2262752: Cellular responses to stress
R-HSA-8862803: Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
R-HSA-3299685: Detoxification of Reactive Oxygen Species
R-HSA-1643685: Disease
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-8863678: Neurodegenerative Diseases
R-HSA-5628897: TP53 Regulates Metabolic Genes
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolPRDX1
Nameperoxiredoxin 1
Aliases NKEFA; PAGA; MSP23; NKEF-A; PRXI; natural killer cell-enhancing factor A; natural killer-enhancing factor A; ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PRDX1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPRDX1
Nameperoxiredoxin 1
Aliases NKEFA; PAGA; MSP23; NKEF-A; PRXI; natural killer cell-enhancing factor A; natural killer-enhancing factor A; ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PRDX1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.12; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.54 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPRDX1
Nameperoxiredoxin 1
Aliases NKEFA; PAGA; MSP23; NKEF-A; PRXI; natural killer cell-enhancing factor A; natural killer-enhancing factor A; ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PRDX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2560.619
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5980.884
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8750.765
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1730.755
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4530.793
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9740.688
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.010.986
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0790.973
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1330.96
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4250.883
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5240.908
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1220.172
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PRDX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPRDX1
Nameperoxiredoxin 1
Aliases NKEFA; PAGA; MSP23; NKEF-A; PRXI; natural killer cell-enhancing factor A; natural killer-enhancing factor A; ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRDX1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPRDX1
Nameperoxiredoxin 1
Aliases NKEFA; PAGA; MSP23; NKEF-A; PRXI; natural killer cell-enhancing factor A; natural killer-enhancing factor A; ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRDX1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRDX1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPRDX1
Nameperoxiredoxin 1
Aliases NKEFA; PAGA; MSP23; NKEF-A; PRXI; natural killer cell-enhancing factor A; natural killer-enhancing factor A; ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRDX1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPRDX1
Nameperoxiredoxin 1
Aliases NKEFA; PAGA; MSP23; NKEF-A; PRXI; natural killer cell-enhancing factor A; natural killer-enhancing factor A; ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PRDX1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPRDX1
Nameperoxiredoxin 1
Aliases NKEFA; PAGA; MSP23; NKEF-A; PRXI; natural killer cell-enhancing factor A; natural killer-enhancing factor A; ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PRDX1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPRDX1
Nameperoxiredoxin 1
Aliases NKEFA; PAGA; MSP23; NKEF-A; PRXI; natural killer cell-enhancing factor A; natural killer-enhancing factor A; ......
Chromosomal Location1p34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PRDX1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PRDX1.
ID Name Drug Type Targets #Targets
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141
DB11638ArtenimolSmall MoleculeACTG1, ALB, ALDH7A1, ALDOA, ANXA2, ATP5A1, ATP5L, ATP5O, CAST, CCT ......79